CN108186643B - Pharmaceutical composition with synergistic osteosarcoma resistance effect and application thereof - Google Patents
Pharmaceutical composition with synergistic osteosarcoma resistance effect and application thereof Download PDFInfo
- Publication number
- CN108186643B CN108186643B CN201810309050.6A CN201810309050A CN108186643B CN 108186643 B CN108186643 B CN 108186643B CN 201810309050 A CN201810309050 A CN 201810309050A CN 108186643 B CN108186643 B CN 108186643B
- Authority
- CN
- China
- Prior art keywords
- osteosarcoma
- apatinib
- gsk
- cells
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000008968 osteosarcoma Diseases 0.000 title claims abstract description 37
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
- 230000000694 effects Effects 0.000 title abstract description 20
- 230000002195 synergetic effect Effects 0.000 title abstract description 11
- WPEWQEMJFLWMLV-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 claims abstract description 41
- 229960003982 apatinib Drugs 0.000 claims abstract description 33
- WBKCKEHGXNWYMO-UHFFFAOYSA-N 3-[[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-4-pyrimidinyl]amino]propanoic acid ethyl ester Chemical compound N=1C(NCCC(=O)OCC)=CC(N2CCC3=CC=CC=C3CC2)=NC=1C1=CC=CC=N1 WBKCKEHGXNWYMO-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229940122680 Demethylase inhibitor Drugs 0.000 claims abstract description 4
- 108010074870 Histone Demethylases Proteins 0.000 claims abstract description 4
- 102000008157 Histone Demethylases Human genes 0.000 claims abstract description 4
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims abstract description 3
- 229940124639 Selective inhibitor Drugs 0.000 claims abstract description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 31
- 238000011282 treatment Methods 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 12
- 230000012010 growth Effects 0.000 abstract description 6
- 230000000259 anti-tumor effect Effects 0.000 abstract description 3
- 210000004881 tumor cell Anatomy 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 40
- 229940079593 drug Drugs 0.000 description 23
- 230000004083 survival effect Effects 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 238000002512 chemotherapy Methods 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 238000003570 cell viability assay Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 101001025967 Homo sapiens Lysine-specific demethylase 6A Proteins 0.000 description 2
- 101001025971 Homo sapiens Lysine-specific demethylase 6B Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 102100037462 Lysine-specific demethylase 6A Human genes 0.000 description 2
- 102100037461 Lysine-specific demethylase 6B Human genes 0.000 description 2
- 206010027458 Metastases to lung Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000002266 amputation Methods 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000011227 neoadjuvant chemotherapy Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 238000012406 Annexin V-FITC/PI double staining Methods 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010059516 Skin toxicity Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000002758 humerus Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000011242 molecular targeted therapy Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000001175 rotational moulding Methods 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A pharmaceutical composition with synergistic anti-osteosarcoma effect and its application are provided. The invention discloses a pharmaceutical composition containing VEGFR2 selective inhibitor Apatinib (Apatinib) and histone demethylase inhibitor GSK-J4 and application thereof. The Apatinib (Apatinib) and GSK-J4 are used in combination, have synergistic antitumor effect, can obviously inhibit the growth of osteosarcoma tumor cells, and can be used for treating tumors such as osteosarcoma.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition with a synergistic anti-tumor effect and application thereof.
Background
Osteosarcoma is a primary malignant bone tumor that originates from mesenchymal cells of bone and is characterized by the proliferation of tumor cells directly forming immature bone or bone-like tissue. The clinical occurrence rate of the typical osteosarcoma is about 0.3/ten thousand, which accounts for about 0.2% of malignant tumor and 15% of primary bone tumor. The typical osteosarcoma is well developed in men, the onset age is 8-25 years, and the osteosarcoma is rare before 6 years and after 60 years; the hair-improving part is a long bone, generally the distal femur or the proximal tibia, and then the proximal humerus, and other parts are rarely seen. The blood circulation and metastasis occur early, the incidence is high, and the progress is rapid. The standard treatment for osteosarcoma was amputation before 1970, but 80% of patients had micrometastases at the time of diagnosis, the mean time from surgical treatment to the appearance of lung metastases was 8 months, the overall survival rate was low in 5 years, and most of patients with tumor lung metastases died within 1 year after diagnosis. Research shows that the 5-year overall survival rate of osteosarcoma patients in China in the last decade is 7.5-77.6%, the average survival rate is 64.0%, the 5-year tumor-free survival rate is 34.8-69.7%, and the average survival rate is 56.0%.
The existing methods for treating osteosarcoma mainly comprise chemotherapy, surgery, radiotherapy, gene therapy, immunotherapy and molecular targeted therapy. The limb protection surgery replaces the existing amputation surgery, but the surgical treatment has limitations, for example, the tumor section bone resection and the joint fusion surgery can cause the loss of joint functions, and the surgical treatment is less clinically applied at present; rotational molding has positive implications for preserving limbs, but its development is limited by its poor appearance. In the aspect of chemotherapy, the current radiotherapy method has poor effect on osteosarcoma and low survival rate of patients, and is generally only used for patients who have pain relieving and cannot excise osteosarcoma.
In the aspect of drug treatment, the chemotherapy field gradually forms a concept of neoadjuvant chemotherapy, but research results show that the neoadjuvant chemotherapy cannot improve the long-term survival rate on the basis of adjuvant chemotherapy. Conventional chemotherapeutic agents also have certain problems, firstly, small doses of conventional chemotherapeutic agents such as Methotrexate (MTX) are not effective in killing tumor cells; although good curative effect is achieved by high-dose chemotherapy, serious toxic and side effects caused by chemotherapy, such as serious granulocyte andor platelet drop and serious infection possibly caused by the serious toxic and side effects are not negligible; resistance problems are also a major cause of chemotherapy failure. Like other therapeutic drugs, molecular targeted therapeutic drugs also produce resistance and adverse reactions. There are mainly skin toxicity, gastrointestinal toxicity reactions, hypertension and adverse cardiac events, as well as effects on the blood, which can be manifested as neutropenia. In recent years, the treatment of osteosarcoma has a bottleneck, and particularly for the treatment of some patients with metastatic osteosarcoma and chemotherapy resistance, an effective osteosarcoma treatment drug is lacked, and a new drug and treatment strategy needs to be developed. Therefore, the development of new drugs and the application of new drug combinations are of great significance for the breakthrough of the progress of the treatment of osteosarcoma.
GSK-J4, with structure shown in formula I, is a histone demethylase inhibitor. The GSK-J4 is thought to inhibit the proliferation of glioma and breast cancer cells by inhibiting the activity of demethylase UTX (also called KDM6A) and JMJD3 (also called KDM6B) of 27 th amino acid of histone H3.
Apatinib, the structure of which is shown in formula I, is also called Einstam, is the only oral preparation in the existing late gastric cancer targeted drugs, and is also an oral drug which is proved to be safe and effective after the late gastric cancer standard chemotherapy fails. A large number of clinical researches show that the apatinib can remarkably prolong the survival time of patients with advanced gastric cancer by inhibiting the generation of new blood vessels in tumor tissues.
Disclosure of Invention
The present invention aims to provide a combination drug having a superior anticancer effect, low toxicity, low side effects, and maximizing efficiency. In view of the above, the present invention provides a pharmaceutical composition and an application thereof.
The invention provides the following technical scheme:
the invention provides a pharmaceutical composition which comprises VEGFR2 selective inhibitor apatinib and histone demethylase inhibitor GSK-J4.
The apatinib and the GSK-J4 are used in combination, the drug effect of the combined use is larger than that of the single drug effect, and the combined use has obvious inhibition effect on the development of osteosarcoma and osteosarcoma.
Tests prove that the technical scheme provided by the invention can obviously inhibit the growth of osteosarcoma cells and has better anti-tumor efficacy.
In some embodiments of the invention, the molar ratio of apatinib to GSK-J4 is (1-3): (1-3).
In some embodiments of the invention, the apatinib is used at a concentration of 10-100 mg/kg; the GSK-J4 is used at a concentration of 5-50 mg/kg.
The invention also provides application of the pharmaceutical composition in preparing a medicament for treating cancer.
In some embodiments of the invention, the osteosarcoma cells are 143B cells and SJSA1 cells.
The invention does not limit the dosage form of the medicine, and all the dosage forms accepted in the field of medicine are in the protection scope of the invention.
Drawings
FIG. 1 shows the inhibition of the survival rate of osteosarcoma cells by apatinib and GSK-J4, respectively, as determined by cell viability assay;
FIG. 2 shows that there is a synergistic effect of the inhibition of the survival of osteosarcoma cells by the two drugs; FIG. 2A is a graph showing the determination of synergy index. FIG. 2B is a graph showing the inhibition of osteosarcoma cell survival by the combination of two agents compared to the inhibition of osteosarcoma cell survival by the combination of two agents alone.
FIGS. 3 to 5 show the detection of the apoptosis-inducing effect of the combination of two drugs and the single drugs of apatinib and GSK-J4 on bone and muscle cells, respectively; wherein, the effects of the drugs on the 143B cells of osteosarcoma cell line are shown in FIG. 3A and FIG. 4, which are a control group, a GSK-J4 group, an apatinib group and a combination group from left to right. FIGS. 3B and 5 show the effect of the drug on the osteosarcoma cell line SJSA1 cells, which are a control group, a GSK-J4 group, an apatinib group and a combination group from left to right.
FIG. 6 shows the inhibitory effect of the combination of two drugs on the tumorigenesis of osteosarcoma 143B cells and SJSA1 cells in experimental animals compared to the corresponding single drug; wherein, FIG. 6A shows 143B cell group, which comprises control group, GSK-J4 group (50mg/kg), apatinib group (100mg/kg), and combination group (GSK-J450 mg/kg plus apatinib 100mg/kg) from top to bottom. FIG. 6B shows SJSA1 group, which is composed of control group, GSK-J4 group (50mg/kg), apatinib group (100mg/kg), and combination group (GSK-J450 mg/kg plus apatinib 100mg/kg) from top to bottom.
Detailed Description
The invention discloses a pharmaceutical composition and application thereof, and can be realized by appropriately improving process parameters by referring to the content. It is expressly intended that all such similar substitutes and modifications which would be obvious to one skilled in the art are deemed to be included in the invention. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications in the methods and applications described herein, as well as other suitable variations and combinations, may be made to implement and use the techniques of this invention without departing from the spirit and scope of the invention.
In the following examples, the inhibition rate + survival rate was 1.
The invention is further illustrated by the following examples:
1. example 1
Apatinib (from sel leck, cat # S2221) and GSK-J4 (from sel leck, cat # S7070) were prepared at different concentrations and were ready for use.
The effect of testing different concentrations of the drugs on the proliferation of human osteosarcoma cells 143B and SJSA1 was examined by MTT assay. 143B (ATCC number CRL-8303. TM., human, epithelial-like adherent growth) and SJSA1 cells (ATCC number CRL-2098. TM., human, epithelial-like adherent growth) in exponential growth phase were trypsinized, blown up into single cell suspensions, counted and plated into 96-well plates. Culturing for 24h in an incubator, adding test drugs with different concentrations after the cells adhere to the walls, stopping culturing after 48h, adding 20 μ l MTT (5mg/mL) into each well, and incubating for 4h at 37 ℃ in a dark place. Then, the liquid in each well is discarded, 150 mu L DMSO is added, the mixture is shaken for 15min, crystals are fully dissolved, and the optical density value of the cells is measured under the 490nm wavelength of a microplate reader.
The MTT method is adopted to respectively detect the inhibition effect of apatinib and GSK-J4 on cells of two cell lines of osteosarcoma. The calculation method of the action relationship of the medicine comprises the following steps: survival rate ═ experimental group number-blank number)/(control group number-blank number)
The experimental results are as follows:
the results show that apatinib and GSK-J4 have certain inhibitory effects on 143B and SJSA1 cells alone (fig. 1).
2. Example 2
And further examining the proliferation inhibition effect of the combination of apatinib and GSK-J4 on 143B and SJSA1 cells, and obtaining a drug interaction index CI through calculation.
Determination by MTT method
Apatinib and GSK-J4, and the combination of the above two drugs, have inhibitory effects on 143B and SJSA1 cell proliferation.
Grouping experiments: experimental groups 143B and SJSA1 cell lines were treated as follows: 1) blank control group: no drug treatment is added; 2) each single medicine group: apatinib group: culturing for 48h under the action of 40, 20, 10, 5, 2.5, 1.25 and 0.625 mu mol/L apatinib; group GSK-J4: culturing for 48h under the action of 20, 10, 5, 2.5, 1.25, 0.625, 0.3125 μmol/LGSK-J4; 3) a combination of drugs: apatinib + GSK-J4 group: 40. 20, 10, 5, 2.5, 1.25 and 0.625 mu mol/L apatinib are respectively cultured for 48 hours under the action of 20, 10, 5, 2.5, 1.25, 0.625 and 0.3125 mu mol/LGSK-J4; each group was set with 3 replicate wells, the experiment was repeated 3 times, and the average was taken as the final result.
Cell viability assay in the same manner as in example 1, Calcusyn software (Bio-soft, Ferguson, Mo., USA) was used in combination with the index assay to analyze synergy index (Combi-indication index, CI), and the results showed that CI <1 is synergistic, 1 is additive and 1 is antagonistic
As a result, when the apatinib and the GSK-J4 are used in combination, synergistic inhibition effect on osteosarcoma cells can be shown under different concentrations (0.1-100 mu g/ml) (figure 2A).
For the SJSA1 cell line, CI >1 when the inhibition rate (fa) < 20%, both had antagonistic effects, with a synergistic effect for fa > 20%; for 143B, the synergistic effect was most pronounced in the fa range, which was around 100% with the lowest CI value (fig. 2A).
Then fixing the proportion and the concentration of the two medicines, and detecting the synergistic effect of the combination. The experimental groups were as follows: 1) blank control group: no drug treatment is added; 2) each single medicine group: apatinib group: culturing for 24h, 48h, and 72h under the action of 10 μmol/L apatinib; group GSK-J4: culturing for 24h, 48h and 72h under the action of 5 mu mol/LGSK-J4; 3) a combination of drugs: the Apatinib 10 mu mol/L and 5 mu mol/LGSK-J4 were cultured for 24h, 48h, and 72 h. For cell viability assays at 24h, 48h, and 72h time points, apatinib in combination with GSK-J4 had a stronger proliferation inhibitory effect on 143B and SJSA1 cells than each single drug group (P <0.05) (fig. 2B).
In order to determine whether the combined use of apatinib and GSK-J4 has stronger apoptosis effect on osteosarcoma cells, the apoptosis induction effect of 143B and SJSA1 cells treated by apatinib and GSK-J4 single drugs and the combination of the two drugs for 12 hours is detected by a flow cytometer by adopting an Annexin V-FITC/PI double staining method.
The experimental process is that different groups of medicaments act on 10 respectively5 Centrifuging 143B or SJSA1 cells for 12h to obtain cells, washing, staining with a double staining reagent annexinV-FITC/PI for 15-20 min, centrifuging, washing, re-suspending with staining Buffer, and performing flow cytometryAnd (3) measuring a fluorescence channel corresponding to FITC/PI, wherein normal cells are FITC-/PI-, cells at the early apoptosis stage are FITC +/PI-, and cells at the late apoptosis stage and necrotic stages are FITC +/PI +.
The results show that, compared with the single drug group, the combined use of apatinib and GSK-J4 has obviously enhanced apoptosis induction effect on osteosarcoma 143B and SJSA1 cells, and the difference has extremely obvious statistical significance (P < 0.01). (FIGS. 3A and 3B, FIGS. 4 and 5).
3. Example 3
Culturing osteosarcoma 143B and SJSA1 cells, digesting with pancreatin when the cells are in exponential growth stage, collecting cells, and preparing into 1 × 10 with sterile physiological saline7one/mL of the cell suspension was injected subcutaneously into the left underarm position of male nude mice, 0.2mL each. The condition of the mice was observed every day, and the major diameter (a) and the minor diameter (b) of the tumor were measured with a vernier caliper according to the formula V (mm)3)＝(a×b2) The tumor volume was calculated. When the tumor volume reaches 80-100 mm3At the time, animals were randomly divided into 4 groups of 5 animals each. Respectively as follows: control group: physiological saline; apatinib group: 100 mg/kg; ③ GSK-J4 group: 50 mg/kg; fourthly, combination group: apatinib 100mg/kg + GSK-J450 mg/kg. The control group, the apatinib group, the GSK-J4 group and the combination group are administrated intraperitoneally once every other day for 5 times continuously. After 27 days, the mice were sacrificed by cervical dislocation, and the tumors were peeled off, weighed, and compared for the size of the tumor growth.
Results of the experiment
As shown in fig. 6, when the two were used in combination, the growth of the transplanted tumor was inhibited to a greater extent. The results show that the combined administration group obviously reduces the sarcoma volume and the tumor weight of the mice.
Claims (3)
1. A pharmaceutical composition for treating osteosarcoma, which comprises VEGFR2 selective inhibitor apatinib and histone demethylase inhibitor GSK-J4, wherein the molar ratio of apatinib to GSK-J4 is 2: 1.
2. The pharmaceutical composition according to claim 1, wherein apatinib is used in a concentration of 10-100 mg/kg; the GSK-J4 is used at a concentration of 5-50 mg/kg.
3. Use of a pharmaceutical composition according to claim 1 or 2 for the preparation of a medicament for the treatment of osteosarcoma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810309050.6A CN108186643B (en) | 2018-04-09 | 2018-04-09 | Pharmaceutical composition with synergistic osteosarcoma resistance effect and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810309050.6A CN108186643B (en) | 2018-04-09 | 2018-04-09 | Pharmaceutical composition with synergistic osteosarcoma resistance effect and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108186643A CN108186643A (en) | 2018-06-22 |
| CN108186643B true CN108186643B (en) | 2021-04-20 |
Family
ID=62596402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810309050.6A Active CN108186643B (en) | 2018-04-09 | 2018-04-09 | Pharmaceutical composition with synergistic osteosarcoma resistance effect and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108186643B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110922587B (en) * | 2019-12-05 | 2023-01-13 | 中山大学 | Preparation method of nano-drug and application of nano-drug in treatment of osteosarcoma |
| CN115381954B (en) * | 2021-05-21 | 2023-12-05 | 深圳市翰慧医药科技有限公司 | Combined medicine for treating osteosarcoma |
| CN115990136B (en) * | 2022-10-31 | 2024-09-03 | 中南大学湘雅三医院 | Antitumor composition, nano preparation, preparation method and application |
| CN115798673B (en) * | 2022-11-25 | 2023-08-08 | 成都诺医德医学检验实验室有限公司 | Combined drug recommendation method and device |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010004283A2 (en) * | 2008-07-11 | 2010-01-14 | The University Of Dundee | Therapy |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107434803B (en) * | 2012-10-02 | 2020-05-05 | 吉利德科学公司 | Inhibitors of histone demethylases |
-
2018
- 2018-04-09 CN CN201810309050.6A patent/CN108186643B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010004283A2 (en) * | 2008-07-11 | 2010-01-14 | The University Of Dundee | Therapy |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108186643A (en) | 2018-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108186643B (en) | Pharmaceutical composition with synergistic osteosarcoma resistance effect and application thereof | |
| US12156861B2 (en) | Pharmaceutical composition for treating kidney cancer and application thereof | |
| Heidenreich et al. | 897 High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer | |
| CN104398526B (en) | The application of triptolide and Celastrol in antineoplastic is prepared | |
| JP2018517759A (en) | Compositions and uses comprising carboplatin | |
| CN110038030A (en) | Anti- nasopharyngeal carcinoma active compound, chemotherapeutics and its application | |
| Tao et al. | Synergistic effect of docetaxel combined with cisplatin on inhibiting human osteosarcoma in nude mice | |
| TWI858454B (en) | Use of chiauranib in treating small cell lung cancer | |
| CN105535003A (en) | Uses of calenduloside E in preparation of anti-tumor medicines | |
| CN111249274B (en) | Application of ginkgolide B in preparation of glioma cell activity inhibitor | |
| KR100519456B1 (en) | Composition for Suppressing the toxicity of anti-cancer treatment | |
| CN109662968A (en) | The liter white preparation of -5 α androstane hydride compounds of carbon loss containing A- and its application | |
| CN112618569A (en) | Medicine for treating urothelial cancer | |
| CN110876803B (en) | A pharmaceutical composition comprising milk protein and oleic acid | |
| CN113116914A (en) | Pharmaceutical composition with synergistic inhibition effect on proliferation of non-small cell lung cancer A549 cells and application thereof | |
| CN108096239B (en) | A pharmaceutical composition for treating brain glioma and hepatocarcinoma | |
| CN111632132A (en) | A pharmaceutical composition for synergistically inhibiting sorafenib resistance of liver cancer and its application | |
| CN114748630B (en) | Platinum anti-cancer medicine composition with improving effect and application thereof | |
| AU2020255063A1 (en) | Combined use of A-nor-5α androstane compound drug and anticancer drug | |
| CN105920604B (en) | Combination medicine for treating leukaemia and its application in treatment leukaemia | |
| CN110063988A (en) | A kind of pharmaceutical composition and preparation method thereof for treating neuroblastoma | |
| CN115381954B (en) | Combined medicine for treating osteosarcoma | |
| CN111840523B (en) | A kind of anticancer pharmaceutical composition containing active protein and active fatty acid | |
| CN115381852A (en) | A kind of compound drug combination with the effect of treating glioma and its use | |
| Ucok et al. | Hyaluronic acid preparations for cosmetic and medical purposes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |